When AI Answers Misrepresent a Healthcare Brand: Risks and Mitigation

Search used to give a list of links, and the brand's own site, the label, and a few medical references usually sat near the top. AI answers compress that into a paragraph. The paragraph may cite sources, or it may not. It may be correct, or it may blend three products into one confident summary. For a prescription brand, that matters in a way it does not for a sneaker brand. Health and medicine are what Google calls "Your Money or Your Life" topics, where errors can cause real harm.

The risks of AI engines misrepresenting healthcare brands

The pattern behind most of these is stale or ambiguous source material. AI systems tend to repeat what is widely published. If old press coverage, a forum thread, or an outdated drug database page says the wrong thing more clearly than your own site says the right thing, the wrong thing can win.

Why this is harder for pharma than for other brands

Three reasons. First, the stakes. A wrong dose is not a reputational annoyance. Second, the rules. Pharma companies communicate under FDA requirements for fair balance and approved claims, and an obvious "fix" like publishing content that answers every off-label question is not available. Third, the process. Any content you publish to correct the record goes through MLR review, which takes time.

The regulatory question of who is responsible for third-party AI output is not settled. In general, content a company did not create or influence is not its promotion. Content it sponsored, paid for, or shaped can be different. Ask regulatory and legal before you decide how to respond. This page is not legal advice.

How to monitor AI answers

Start with a fixed prompt set so results are comparable month to month.

1. Write 20 to 40 prompts across the questions real people ask: what is the drug for, how is it taken, side effects, compared with a named competitor, cost, who should not take it. Include HCP-style prompts too.
2. Run them across the AI tools your audiences use. Record the date, tool, prompt, full answer, and cited sources.
3. Score each answer against the current label: correct, incomplete, outdated, or wrong. Flag anything about dosing or safety for priority review.
4. Track which sources get cited. That list tells you where to focus.
5. Repeat monthly and after any label update or major news.

The existing article on monitoring AI search citations explains why to treat this as a quality audit and not as a ranking report. Answers vary run to run, so look for patterns, not single outputs.

How to mitigate: fix the sources

You cannot rewrite an AI answer. You can change what it learns from and cites.

• Make your own pages clear. State the indication, dosing, and key safety information in plain text near the top of the relevant page, consistent with the label. Avoid hiding it in images or PDFs only.
• Keep dates and versions visible. A "last updated" date and label version help both people and systems pick the current page.
• Use structured content. Clear headings, short factual statements, and appropriate schema markup make pages easier to parse. Google's guidance on helpful, people-first content applies here, and the article on AI search visibility for healthcare expertise covers what site owners can control.
• Ask third parties to correct errors. If a drug database, a health publisher, or a reference site has outdated information that keeps getting cited, contact them. Medical information teams often already have a process for this.
• Use platform feedback tools. Most AI tools have a way to flag an answer. It is not a guaranteed fix, but document that you used it.
• Retire old pages. Old campaign microsites and press releases with superseded information keep getting cited. Redirect or update them.

Adverse event and medical information considerations

Monitoring AI answers can surface things your pharmacovigilance team needs to see. An AI summary itself is usually not an adverse event report, because there is no identifiable patient or reporter. But the cited sources may include forums or reviews where a real person describes a reaction. Agree upfront with your safety team on what the monitoring team should forward and how fast. The FDA's MedWatch program is the public channel for safety reporting, and your company's own AE procedures govern internal handling.

Also loop in medical information. They answer unsolicited questions from HCPs and patients, often have approved standard responses, and are well placed to judge whether an AI answer is materially wrong.

Who should own this

In most companies, nobody does yet. Brand teams see it as a search issue, digital teams see it as a content issue, and regulatory sees it as a marketing question. A workable setup: digital or search owns monitoring, medical information owns accuracy review, regulatory signs off on any published response, and pharmacovigilance gets a defined handoff. Put it in a short SOP and give it a monthly slot, the same way you would treat any other brand safety question. It belongs in the broader quality conversation covered in the programmatic media quality guide, even though it sits outside paid media.

Practical takeaway

Write 25 prompts about your brand, run them in the three AI tools your patients and HCPs most likely use, and score each answer against the current label. Share the results, with every dosing or safety error highlighted, with medical information and regulatory in the same meeting.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.